Carolyn Bertozzi is an esteemed chemist and bioengineer who has contributed significantly to the field of therapeutics. She is currently a chemistry and chemical and systems biology professor at Stanford University, as well as a co-founder of several biotech companies.
Bertozzi’s career began as a postdoctoral researcher at the University of California, Berkeley, where she studied carbohydrate chemistry and bioconjugation. She later became a member of the faculty at the University of California, Berkeley, where she established a research program aimed at developing new methods for imaging and manipulating biological systems.
Bertozzi has been a successful biotech entrepreneur in addition to her academic research. One company she co-founded, Redwood Bioscience, is developing new protein drug conjugation technologies. Another is Palleon Pharmaceuticals, which is developing novel cancer and inflammatory disease therapies.
Bertozzi has received numerous awards and honors for her contributions to therapeutics and biotech entrepreneurship, including the 2022 Nobel Prize in Chemistry, MacArthur Fellowship, the National Medal of Science, and the Breakthrough Prize in Life Sciences. Her research has aided in the development of new treatments for a variety of diseases, and her novel approaches to bioconjugation and glycoengineering have opened up new avenues for drug discovery and development.